Select Location
What is your delivery location?
We need your delivery location to continue browsing
Select Location
We need your delivery location to continue browsing
Prescription Required
dr.reddy
28 tablet
Sofosbuvir and Ledipasvir
Keep in cold place
Delivering To:
Overview
Resof-L Tablet is an antiviral medication, which is used in combination with other medicines. It is used in the treatment of chronic hepatitis C virus (HCV) infection. It stops or prevents the growth of viruses in the body and helps remove the virus from the blood. Resof-L Tablet helps you to recover faster and control the infection from spreading in your body. This is a prescription-based medicine, which is to be taken only when prescribed by your doctor.
Hepatitis C
Treatment of Chronic hepatitis C virus (HCV) infection
The human body reacts differently to Resof-L Tablet. Response or undesired symptoms vary from individual to individual. Usually, they disappear with time as the body adjusts to the medicine; these side effects don't need special medical attention. Whereas if the symptoms don't disappear with time or you have severe side effects, then consult your doctor immediately. Some of the common side effects of Resof-L Tablet are mentioned below:
Headache
Fever
Chills
Nausea
Insomnia (difficulty in sleeping)
Tiredness
Loss of appetite
Fatigue Anemia (low number of red blood cells)
Skin rash
Take the dose of Resof-L Tablet as per your healthcare provider’s prescription. Do not stop taking the medicine suddenly, unless your doctor tells you. This medicine is given under the strict supervision of a doctor. Do not self-administer. Overdose is a very unusual state for this medicine because it is given under the supervision of a healthcare provider. Resof-L Tablet can be taken without food or with food. The doctor will provide emergency medical treatment. You should not break, crush, or chew the medicine; it should be swallowed as a whole. It is advised to eat a healthy diet and drink plenty of fluids to overcome and prevent the side effects that have occurred after taking Resof-L Tablet.
Resof-L Tablet is an antiviral medicine made up of Sofosbuvir and Ledipasvir. Both ingredients present in the medicine prevent the virus from multiplying. Thus, the viral count in the blood gets lowered, and the infection can be eliminated from the body. This medication is suitable for use in both adults and children aged three years and above. Resof-L Tablet inhibits an important Nonstructural protein 5A (NS5A) and viral phosphoprotein, which are involved in replication of the virus, assembly, secretion, and RNA viral production.
Alcohol
unsafe
The interaction of alcohol with this drug is still unknown. It is advisable not to consume alcohol while taking Resof-L Tablet. Consult your doctor for further information.
Pregnancy
consult your doctor
Resof-L Tablet may be considered unsafe during pregnancy. Please consult your doctor in such a condition. According to some research data, taking Resof-L Tablet during pregnancy has shown harmful effects on the developing baby.
Breast Feeding
consult your doctor
Resof-L Tablet is probably not safe if you're breastfeeding. Kindly consult your doctor before taking Resof-L Tablet while breastfeeding, as there are chances that it may pass to the developing baby through the breast milk of the mother.
Driving
danger
It is advisable not to drive or operate heavy machinery after taking Resof-L Tablet, as you may feel dizzy.
Kidney
precaution
Share your medical history with your healthcare expert in case of kidney disease before taking Resof-L Tablet. Patients with renal impairment must be careful while taking Resof-L Tablet. They may require adjustment in the dose.
Liver
precaution
Inform your doctor before starting Resof-L Tablet if you have liver disease to avoid any serious side effects. Patients with hepatic impairment must be careful while taking Resof-L Tablet. They may require adjustment in the dose.
Resof-L Tablet is an antiviral medication, used along with other medications, in the treatment of chronic Hepatitis C Virus (HCV) infection in adults.
Take the Resof-L Tablet exactly as your healthcare provider tells you. Do not alter the dose strength on your own. Do not crush, chew, or break the tablet.
Side effects of Resof-L Tablet are fever, nausea, anemia, insomnia, chills, muscle pain, cramps, fainting, and skin rash. If you experience these or any other side effects, make sure to consult your healthcare provider for the same.
Avoid the consumption of fatty or sugary foods and alcohol.
Do not drive or operate heavy machines if you feel unwell after taking this medicine.
If you miss a dose of Resof-L Tablet, take it as soon as you remember. Do take an extra dose of the medicine to make up for the missed one.
It is important to complete the full course of the Resof-L Tablet as prescribed by the doctor. If you feel better, then you should also not stop taking Resof-L Tablet, as it may worsen your symptoms.
Time may vary from individual to individual, depending on the severity and stage of the disease. But it is essential to complete the full course of the Resof-L Tablet.
Consult your doctor before taking any supplements or vitamins to prevent any kind of interactions with Resof-L Tablet, which can cause severe effects to the individual.
No, Resof-L Tablet is not a habit-forming medicine.
At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.
Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.
Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.
We currently ship to:
Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!
Abergel A, Asselah T, Metivier S, Kersey K, Jiang D, Mo H, Pang PS, Samuel D, Loustaud-Ratti V. (2023). Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 16(4):459-64.
Duc N. T, Vittorio F, Alexander Z, Venkat R. G, Akihiro H, Mingjun H, Jason A. W. (2025). The Discovery and Chemical Development of Odalasvir, a Potent and Selective HCV NS5A Inhibitor, Complete Accounts of Integrated Drug Discovery and Development: Recent Examples from the Pharmaceutical Industry Volume 5, 1-58.
Lele Z, Matthew H, Prahalad G, Mahan G, Steven K, Haiting C, Paul K, Eleanor B, M. Azim A, Katrina L, Genetically distinct within-host subpopulations of hepatitis C virus persist after Direct-Acting Antiviral treatment failure, PLOS Pathogens, 21, 4, (e1012959).
Nambaru Vidya Sagar, Anamika Goyal, Abhishek Raj, Subhash Chandra, Upendra Nath Gupta, Prabhat Agrawal, Rajat Gupta, Rahul Agrahari. (2024). SVR timelines in hepatitis irrespective of viral genotype: An Indian perspective, Journal of Family Medicine and Primary Care, 14, 4, 1425-1430.
Preferred Therapy for Specific Viral Pathogens, Nelson’s Pediatric Antimicrobial Therapy, (2025).
Thomas R. O, David J. W, Varun S, Kerry G.M., Sabrina C, Francine S.B., Ludmila P. O, Ruth M. P, Jennifer B. L. (2024). IFNL4 genotype and other personal characteristics to predict response to 8-week sofosbuvir-based treatment for chronic hepatitis C, Journal of Infection, 89, 5, (106258).
Yong P, Sitthichai K, Nungruthai S, Pornjarim N, Ritthideach Y, Wijittra P, Napaporn P, Chatree J. (2025). Microelimination of Hepatitis C in Thailand, Phetchabun Model: Progress, Challenges, and Future Directions, Journal of Clinical Medicine, 14, 11, 3946.
dr.reddy
Written By
Venika Choudhary
Medical Content Writer @ Magicine Pharma
I hold an M.Sc. in Microbiology and have a strong academic foundation in microbial sciences and applied biotechnology. I began my career with extensive hands-on research at CSIR laboratories, focusing on fungal enzyme production, studying fungal diversity in various ecosystems, and developing bio-pesticides as sustainable alternatives to chemical pesticides. This work deepened my understanding of fungal biology, bioactive compounds, and their pharmaceutical and agricultural applications. Transitioning from research, I now work as a medical content writer, where I combine my scientific expertise with a passion for clear and reliable healthcare communication. I apply my research background to create patient-friendly, compliant content for pharmaceutical companies and healthcare platforms, ensuring science is both trustworthy and accessible. Specializing in clear, accurate, and engaging content, I help patients make informed decisions and support pharmaceutical companies in delivering trusted information. Whether writing product descriptions, crafting disease awareness articles, or composing drug information leaflets, I consistently meet regulatory standards and address audience needs, making my content an asset for healthcare brands.
Reviewed By
Dr. Aditya Sarin - MBBS, MD, DrNB - Consultant Medical Oncology
Dr. Aditya Sarin, MBBS, MD, DrNB, is a highly qualified medical oncologist with profound research and clinical expertise, currently working at Sir Ganga Ram Hospital, New Delhi. He is also a member of the European Society of Medical Oncology (ESMO), a non-profit European organization dedicated to eradicating cancer by promoting comprehensive cancer care and advancing medical oncology. He has been honored with several awards, including the International Cancer Foundation scholarship (ESMO congress, 2022) and Young Medical Oncologist of the Year (Times of India, 2024). He is well-known for his breakthrough in oncology. Dr. Sarin is passionate about converting complex health information into a concise and clear form that is understandable to everyone, aiming to create awareness and cancer care among people.